HCW Biologics Inc. Common Stock
HCWBHCW Biologics Inc. (HCWB) is a biopharmaceutical company focused on developing immunotherapy treatments utilizing natural killer (NK) cell-based platforms. The company aims to address various unmet medical needs through innovative therapies that leverage the body's immune system to target and destroy cancer cells. HCW Biologics is involved in research and development efforts to advance its pipeline of biologic products with potential applications in oncology and other therapeutic areas.
Company News
HCW Biologics Inc. (NASDAQ: HCWB) announced a 1-for-6 reverse stock split effective June 30, 2026, to ensure compliance with Nasdaq's minimum bid price rule following a Hearings Panel decision. The company successfully maintained stock prices above $1.00 per share for the required 20 trading days and will reduce outstanding shares from approximat...
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced the pricing of a $1.5 million follow-on offering of 2,477,292 units at $0.6055 per unit. The company plans to use net proceeds for preclinical and clinical development of HCW9302 and general corporate purposes. Additionally, HCW Biologics negotiated to reduce...
HCW Biologics showcased its lead product candidate HCW11-040, a multi-functional fusion protein combining pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, which demonstrates potential to expand exhausted T cells without side effects in cancer treatment.
HCW Biologics announced the selection of HCW11-040, a multi-functional fusion protein, as its lead product candidate for treating solid tumors. The immunotherapeutic combines pembrolizumab with specific cytokines and shows promising preclinical results in expanding T-cell responses without triggering cytokine storm.
HCW Biologics announced successful development of second-generation T-cell engagers targeting solid tumors, particularly pancreatic cancer and glioblastoma, with promising preclinical safety results in non-human primates and potential for treating multiple cancer types.
